It's obvious Marshall made his move when he did because he saw an opportunity to grab the assets on the cheap. He didn't expect the Chapter 7 move which jeopardized an easy take over.
So plan B. Marshall or whoever, put up the $200k as a stopgap measure to keep the FDA thing going and knowing he would get it back as first in line at liquidation. After August the company is broke again and still no where near final FDA approval.
Being a creditor who is in line to gobble up the liquidation assets, he is counting on outbiding competitors because the money involverd is just going from one pocket to the other. It wouldn't surprise me to see him put up even more making it more expensive to bid against him.
It seems Shannon is only concerned with the technology and the jobs of his staff. He is just along for the ride until things settle out.
Nowhere in any of this is any concern for shareholders.